Search

Your search keyword '"Hirschfield, G."' showing total 475 results

Search Constraints

Start Over You searched for: Author "Hirschfield, G." Remove constraint Author: "Hirschfield, G."
475 results on '"Hirschfield, G."'

Search Results

1. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis

2. A43 LONG-TERM EFFICACY AND SAFETY OF OBETICHOCLIC ACID IN PRIMARY BILIARY CHOLANGITIS: RESPONDER ANALYSIS OF OVER 5 YEARS OF TREATMENT IN THE POISE TRIAL

3. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?

4. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

5. Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival

6. Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe

7. Corrigendum to: “An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs” [J Hepatol 75 (2021) 572-581, (S0168827821003342), (10.1016/j.jhep.2021.04.055)]

11. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis

12. Longer transplant-free and liver-related event-free survival in obeticholic acid-treated patients with primary biliary cholangitis compared to external controls from two large real-world cohorts

13. Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls

14. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

15. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

16. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.

18. A44 A 1000 PATIENT CANADIAN NETWORK FOR AUTOIMMUNE LIVER DISEASE EVALUATION OF CLINICAL AND DEMOGRAPHIC PATTERNS OF AUTOIMMUNE HEPATITIS

19. A42 LIVE DONOR LIVER TRANSPLANTATION IN PRIMARY SCLEROSING CHOLANGITIS: AN INDICATOR OF AN ORGAN ALLOCATION SYSTEM NOT ADDRESSING PATIENT NEED

22. Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool

23. Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom

24. A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients

25. A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis

26. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

27. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

28. Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation

29. HLA haplotypes in primary sclerosing cholangitis patients of admixed and non‐European ancestry

33. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis

34. Machine learning in primary biliary cholangitis: A novel approach for risk stratification

35. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

37. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

40. Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis

41. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis

43. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis

46. P066 Lower serum concentration of sulfated bile acids is associated with Primary Sclerosing Cholangitis Inflammatory Bowel Disease comorbidity and advanced liver fibrosis

49. Autoimmune hepatitis cholestatic variant syndromes recurrence following liver transplantation affects graft and patient survival in an international multicentre cohort

Catalog

Books, media, physical & digital resources